Asset Details
Do you wish to reserve the book?
Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis
Do you wish to request the book?
Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis
2025
Overview
Liver sinusoidal endothelial cells (LSECs) lose their characteristic fenestrations and become capillarized during the progression of liver fibrosis. Mesenchymal stem cell (MSC) transplantation can reverse this capillarization and reduce fibrosis, but MSC therapy has practical limitations that hinder its clinical use. Here, with the help of artificial intelligence (AI), we show that MSCs secrete a microRNA (miR-325-3p) that helps restore LSEC fenestrations (tiny pores) by modulating their cytoskeleton, effectively reversing capillarization. We further develop a spherical nucleic acid (SNA) nanoparticle carrying miR-325-3p as an alternative to MSC therapy. This SNA specifically enters fibrotic LSECs via the scavenger receptor A (Scara). In three mouse models of liver fibrosis, the SNA treatment restores LSEC fenestrations, reverses capillarization, and significantly reduces fibrosis without adverse effects. Our findings highlight the potential of SNA-based therapy for liver fibrosis, paving the way for targeted nucleic acid treatments directed at LSECs and offering hope for patients.
RNAi therapies have potential to treat a range of diseases including liver fibrosis. Here, the authors report on the delivery of miR-325-3p in nucleic acid spheres, which can enter the liver sinusoidal endothelial cells, reversing their capillarisation, treating liver fibrosis in mice.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/109
/ 13/31
/ 13/51
/ 13/89
/ 14/19
/ 14/28
/ 38/77
/ 38/91
/ 45/100
/ 631/80
/ Acids
/ Animals
/ Endothelial Cells - drug effects
/ Endothelial Cells - metabolism
/ Endothelial Cells - pathology
/ Fibrosis
/ Humanities and Social Sciences
/ Humans
/ Liver
/ Liver Cirrhosis - metabolism
/ Male
/ Mesenchymal Stem Cell Transplantation
/ Mesenchymal Stem Cells - metabolism
/ Mice
/ miRNA
/ Science
/ Therapy
